| Abbreviation | Definition |
| ADC | antibody–drug conjugate |
| ADT | androgen-deprivation therapy |
| ARPI | androgen receptor pathway inhibitor |
| ctDNA | circulating tumour DNA |
| dMMR | mismatch repair deficient |
| FDG | fluorodeoxyglucose |
| HRR | homologous recombination repair |
| IPCW | inverse probability of censoring weighting |
| ITT | intention to treat |
| mCRPC | metastatic castration-resistant prostate cancer |
| mHSPC | metastatic hormone-sensitive prostate cancer |
| MSI-H | microsatellite instability high |
| NEPC | neuroendocrine prostate cancer |
| NSE | neuron-specific enolase |
| ORR | objective response rate |
| OS | overall survival |
| PARPi | poly(ADP-ribose) polymerase inhibitor |
| PSA | prostate-specific antigen |
| PSMA | prostate-specific membrane antigen |
| RLT | radioligand therapy |
| rPFS | radiographic progression-free survival |
| SUV | standardised uptake value |